SKELID
LOE ApproachingNDAORALTABLET
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKELID is an oral small-molecule tablet approved in 1997 by Sanofi for an undisclosed indication. The mechanism of action and specific therapeutic use are not publicly detailed in available data, limiting characterization of its clinical role.
LOE Approaching
Loss-of-exclusivity is imminent, signaling a contracting brand team and shift toward generic transition or discontinuation planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SKELID currently has zero linked job openings, reflecting its LOE stage and declining commercial relevance. Roles available are typically focused on managed care, reimbursement, and transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on SKELID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.